Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a ...

Shares of Becton Dickinson & Co. BDX shed 1.02% to $237.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,086 ...

近日，贝克顿·迪金森公司 (Becton Dickinson & Co) (NYSE: BDX )执行副总裁兼首席ISC官Shan David出售了500股公司普通股。每股售价为240.00美元，总计12万美元。此次出售后，David仍持有公司5,741股股份。

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...

贝克顿·迪金森公司 (Becton Dickinson & Co.) (NYSE: BDX )执行副总裁兼医疗部门总裁Michael David Garrison最近出售了597股公司普通股。这些股票以平均价格236.51美元售出，交易总额为141,196美元。此次出售后，Garrison直接持有5,544股。

Barclays analyst Matt Miksic lowered the firm’s price target on Becton Dickinson (BDX) to $278 from $312 and keeps an Overweight rating on the ...

Becton, Dickinson's stock momentum is improving, but geopolitical risks and global headwinds warrant caution. Click here to ...

Becton Dickinson's (NYSE:BDX) stock is up by 4.3% over the past month. As most would know, long-term fundamentals ...

Gateway Investment Advisers LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by ...

Compared to the aggregate P/E ratio of the 69.75 in the Health Care Equipment & Supplies industry, Becton Dickinson Inc. has a lower P/E ratio of 40.32. Shareholders might be inclined to think that ...